Cardiologists at Sheffield Teaching Hospitals NHS Foundation Trust have performed a cutting-edge heart valve replacement ...

The five new programmes are designed to fit alongside full-time work and clinical practice Learna and the University of Wolverhampton have partnered to launch five new master’s and postgraduate ...

There are around 55,100 new prostate cancer cases in the UK every year HBC Immunology (HBCI) has announced that an oral formulation of its lead peptide “significantly augmented” the anti-tumour ...

PharmaTimes is the UK’s leading pharmaceutical magazine, tracking the trends and issues that affect the industry here in the UK, in Europe and across the world. We deliver independent, authoritative ...

The 2018 Communications Team of the Year awards are now open for entry, so on p32 we thought we’d ask some top pharma communicators what trends and issues comms teams need to be paying attention to ...

As the polls tighten and June’s general election starts to seem very close indeed, we’ve got a roundup of all the major parties’ manifestos and what they would mean for healthcare in the UK. But ...

Here’s to new beginnings and breaking new ground. I’m absolutely delighted to take on the role of editor of PharmaTimes, on both a personal and professional level. I’m particularly thrilled to take ...

Cancer Grand Challenges, a pioneering initiative co-founded by Cancer Research UK and the US National Cancer Institute (NCI), has launched a global search to identify the most pressing challenges in ...

NK:IO has appointed Richard Hopkins as Chief Executive Officer NK:IO has appointed Richard Hopkins, an experienced biologics developer, as its new Chief Executive Officer. Hopkins has more than 14 ...

As winter looms, so too does a name that sends chills through our collective soul – COVID-19. The pantomime baddie we hoped we’d seen the back of. In reality, COVID-19 does not represent the ...

Pharma has long battled with demonstrating its value to society, tightly holding on to the innovation story as a key channel of communicating its worth to stakeholders in health and care. The trouble ...

The Scottish Medicines Consortium (SMC) has recommended MSD’s KEYTRUDA (pembrolizumab) as a monotherapy for adults with non-small cell lung carcinoma (NSCLC) who are at high risk of recurrence ...